Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAPOR: Personalized Treatment for Poor-Prognosis NSGCT
NCT05705687Phase 4Recruiting
- Sponsor
- Gustave Roussy
- Start
- May 2023
- Primary completion
- Feb 2031
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 4 trial of cisplatin, etoposide, bleomycin, paclitaxel, ifosfamide in non-seminomatous germ cell tumor (NSGCT), sponsored by Gustave Roussy. Started May 2023; status: recruiting.
02
Drugs
cisplatinetoposidebleomycinpaclitaxelifosfamide
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on NCT05705687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705687.